Latest news with #Qure.ai
Forbes
3 days ago
- Health
- Forbes
How AI Powered Med-Tech Can Scale Accessible Healthcare In India
Dr. Ashwini Kumar, Founder, CliniExperts. Helping Global Med-Tech Brands Navigate Indian Healthcare Landscape. In India, every eleven seconds, someone is diagnosed with tuberculosis. Every eight minutes, another case of cervical cancer claims a woman's life. These are more than just numbers; these are people with stories we cannot ignore. But what if technology could hear even what we cannot? Today, artificial intelligence (AI) is not just scanning slides or reviewing scans. It's doing something far more human—it's listening. It's noticing. It's learning from millions of data points and drawing conclusions with breathtaking speed. How AI-Enabled Innovation Is Rewriting The Rules Of Diagnosis Let's look at some of the tools that are already changing how we diagnose, detect and treat these critical health conditions: • Swaasa: A cough analysis tool developed for TB screening, capable of identifying distinct acoustic signatures of respiratory illnesses. It's enabling frontline health workers to screen large populations with nothing but a smartphone—no sputum, no X-ray. • qXR by An AI-driven chest X-ray solution designed to spot signs of TB, pneumonia and lung nodules quickly and reliably. Already deployed in government TB programs and mobile vans across India. • qTrack by A companion system to qXR that allows seamless integration of teleradiology workflows in underserved areas—scaling quality diagnostics to remote districts. • iBEX by Ibex Medical Analytics: A clinical-grade AI platform that supports pathologists in identifying breast cancer with high sensitivity, particularly useful in high-volume, resource-limited environments. • Arogya Arohan: An AI-based app that helps detect early oral cancers via smartphone images—vital for rural and underserved populations where regular screening is a challenge. • CerviSCAN: A visual AI-based cervical cancer screening platform, eliminating the need for complex lab-based pap smear testing in field settings. • TxGNN: An advanced graph neural network used in rare disease drug discovery and repurposing. With 49% higher precision in drug match identification, it's accelerating treatment development for conditions often left behind. • Watson For Oncology by IBM Watson Health: IBM's AI that assists oncologists by reviewing patient records and global literature to recommend personalized treatment plans—bringing world-class cancer expertise to every hospital. • Varian's AI-Enhanced Radiotherapy: AI integrated with imaging to optimize radiation dosage in real time, reducing side effects and improving outcomes. Each one of these tools acts as a second set of eyes, ears and clinical intuition—designed to empower doctors, not bypass them. As a result, AI is pushing 'early detection' into a new paradigm—preemptive healthcare. It's not just about catching diseases early; it's about forecasting risk, personalizing interventions and tracking real-time treatment responses. Whether it's adjusting radiation doses mid-session with Varian systems or designing treatment blueprints with Watson for Oncology, AI is becoming the quiet, indispensable co-pilot in some of medicine's most critical decisions. Where Do We Go From Here? For healthcare and technology leaders, the question is no longer whether to innovate—but how to innovate with intention. The gap between a promising AI prototype and meaningful patient impact is filled by decisions made today in boardrooms, clinics and policy circles. I believe India is uniquely positioned to lead this transformation, set an example for the world to follow suit and improve their healthcare at the same time. They possess a vast, diverse population, deep AI talent and a public health system ready for digital augmentation. But with great speed must come great scrutiny. As the tools evolve, so must the regulatory frameworks, validation mechanisms and ethical guardrails that govern them. Leading The Transformation First, build responsible partnerships. Companies must engage not only data scientists but also clinicians, regulators and public health experts from day one. Co-developing AI solutions alongside end users ensures that the final product is usable, explainable and implementable at ground zero. Second, treat regulatory strategy as an enabler, not a hurdle. Healthcare and tech leaders looking to invest in India's potential must understand India's CDSCO pathways, stay informed on global frameworks like the EU MDR for SaMD and invest early in local clinical validation. Working with experts who understand both innovation and compliance can mean the difference between a pilot that stalls and a product that scales. Finally, never lose sight of patient welfare. AI must serve people, especially the millions who rely on India's public health systems. Leaders should champion solutions that strengthen PHCs, rural diagnostics and community health—where these tools can save the most lives. Putting Patients At The Center If we embed transparency, ethics and real-world training into every stage of development, we will not just build smarter devices—we will build trust in the systems that deliver them. When innovation meets intention, technology becomes more than code. It becomes care. Because the real future of medicine isn't just AI. It's AI, access and accountability. And the entire med-tech industry will reinvent itself when we see innovation meet intention. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Business Wire
26-06-2025
- Business
- Business Wire
Qure.ai Recognized Among TIME's 100 Most Influential Companies of 2025
NEW YORK--(BUSINESS WIRE)-- the world's most widely adopted digital health innovator, has been named to TIME's 2025 TIME100 Most Influential Companies list. Now in its fifth year, the TIME100 list highlights companies making an extraordinary global impact through innovation, ambition, and measurable success. TIME's editorial spotlighted work in advancing diagnostic equity through AI, stating: 'Trained on one of the world's largest data sets, algorithms are as accurate as a radiologist, according to the company, providing crucial insights in rural or developing areas where specialists may not be available. tools have now been deployed in more than 100 countries, and the company has 18 FDA clearances—the greatest number for lung cancer AI in the U.S.—including three new approvals in 2024.' was selected alongside iconic and dynamic brands such as Abbott, Midi Health, Vertex Pharmaceuticals, Function Health, Gilead, CRISPR Therapeutics, NBBJ, and Northwell Health, and is featured in the Pioneer category among health tech AI firms on the 2025 list. Speaking on the recognition, Prashant Warier, CEO and Founder said, 'To be named among TIME's 100 Most Influential Companies is an acknowledgment of a simple but urgent belief: that access to timely, high-quality diagnostics should not depend on where you live. This honor reflects the dedication of our teams and partners across continents, working to close the gap between innovation and impact. This recognition pushes us to keep advancing that future, where care begins long before crisis.' This milestone recognition follows a pivotal year for marked by accelerated momentum in the United States. With over 18 FDA-cleared findings and the launch of its Lung Cancer Care Continuum, a portfolio of AI solutions to detect, measure, and manage lung nodules; now offers an end-to-end suite that supports earlier lung cancer diagnosis across diverse care settings. Backed by a strategic Series D round led by global investors including Lightspeed, 360 One Asset, and the Merck Global Health Innovation Fund, the company is scaling its commercial and clinical impact worldwide. On the global front, continues to lead in innovation for low- and middle-income countries, drawing on its deep experience in TB surveillance at scale. Its newest offering, Aira, a multi-disease clinical AI co-pilot, was launched at the World Health Assembly in Geneva to support care coordination in resource-constrained settings. To compile this year's TIME100 list, TIME's editors evaluated nominees across sectors based on impact, innovation, ambition, and success, after polling its global network of journalists and outside experts. The final list spotlights 105 companies helping chart a path forward for the world. See the full list here: About is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical conditions to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.
&w=3840&q=100)
Business Standard
17-06-2025
- Business
- Business Standard
Quadria Group announces HealthQuad Fund III with $300 million corpus
Private equity firm Quadria Group on Tuesday announced the launch of HealthQuad Fund III, with a target corpus of $200 million and a $100 million in greenshoe option. HealthQuad Fund III succeeds Funds I and II, which have supported over 18 healthcare companies, including Medikabazaar, THB, Wysa, Ekincare, Redcliffe Labs, GoApptiv, and Strand Life Sciences. Quadria Group is aiming to raise $300 million (about Rs 2,550 crore) for its HealthQuad Fund III. Quadria Group has retained a large part of the existing investment and investment committee team members, who will continue to be involved in the existing portfolio investments, a company statement said. It will also add more people to its investing, operating and clinical team. "India presents one of the world's most compelling healthcare investment opportunities, driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care. "With the full ownership of Fund III and expanded leadership, we are better positioned than ever to deliver cross-regional value for our portfolio companies, across South Asia, Southeast Asia, and the GCC, creating an unparalleled platform for health innovation," Amit Varma, co-founder and Investment Committee member, HealthQuad, said. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
17-06-2025
- Business
- Time of India
Quadria Group launches third HealthQuad fund with a corpus of $300 million
MUMBAI: Quadria Group, a healthcare-focused private equity platform on Tuesday announced the launch of HealthQuad Fund III, with a proposed raise of up to $300 million. The fund seeks to back healthcare ventures that have significantly expanded access, affordability, and quality of care across India. Funds I and II backed over 18 companies including Medikabazaar, THB, Wysa, Ekincare, Redcliffe Labs, GoApptiv, and Strand Life Sciences. Dr. Amit Varma, Co-founder and Investment Committee member, HealthQuad, said, 'India presents one of the world's most compelling healthcare investment opportunities—driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care. With the full ownership of Fund III and expanded leadership, we are better positioned than ever to deliver cross-regional value for our portfolio companies, across South Asia, Southeast Asia, and the GCC, creating an unparalleled platform for health innovation. ' Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
23-05-2025
- Health
- Time of India
Qure.ai launches AI tool to aid health workers in LMICs
Mumbai: AI solution provider company has introduced AIRA, an AI-powered co-pilot tool for frontline healthcare workers in low- and middle-income countries (LMICs) at the 78th World Health Assembly in Geneva this week. The company states that community health workers spend over 40 per cent of their time on manual data collection, yet many countries still lack sufficient population-level data for decision-making. According to the company, AIRA is designed to ease the burden on healthcare workers by automating symptom and patient history collection, supporting adherence to clinical protocols, and generating population-level health insights . It aims to address key challenges in LMICs, including a projected shortage of 11 million health workers by 2030 and the 17 million preventable deaths that occur annually. 'With AI, we can multiply every dollar spent and realize significantly more impact and returns in LMIC health systems,' said Prashant Warier, CEO and Founder,
